Business Wire

New Tholos Foundation Report Reveals Flavour Bans Threaten Europe's Smoke-Free Ambition

Share

The Tholos Foundation, an international non-governmental organization dedicated to advocating for consumers, today launched three white papers exposing the risks of banning flavours in vaping products at an event in Brussels hosted by Parliament Magazine and featuring contributions from Swedish MEP Johan Nissinen. The reports cover the impact of flavour bans in the real world, best practices to educate adult smokers and restrict underage usage, and analyse the public response to the European Commission’s 2023 public consultation.

Surveys commissioned by the Tholos Foundation and conducted by Ipsos in multiple countries have shown that a significant majority of vapers use flavours other than tobacco to help reduce and quit smoking. Notably, 83% of vapers in Germany stated that flavours are crucial in their decision to vape, with similar high percentages reported in Belgium, the Netherlands, and Sweden. The research also showed that, in countries where flavours were banned, many vapers went back to smoking or for black market alternative, and reference numerous scientific studies confirming that flavours are essential for the effectiveness of vaping products in smoking cessation.

With European elections due to take place shortly, it is imperative policymakers take heed of voters’ concerns and reject extensive restrictions on lifesaving smoking alternatives. The new European mandate is expected to drive a new revision of the bloc’s Tobacco Products Directive, and consumers have already overwhelmingly responded to a public consultation overwhelmingly stressing the importance of vapes in helping them quit smoking.

Rather than product bans, the papers examine a menu of policy alternatives to protect public health focussing on improved enforcement of existing laws, restricting flavour descriptors and communications, limiting sales to adult-only stores, and an openness to technological innovations.

Tim Andrews, Director of Consumer Issues and a report author said: “The evidence is clear: flavours in vaping products are critical to helping smokers quit. Banning flavours will create a black market and drive people back to smoking. Our reports offer an evidence-based approach that combines rigorous law enforcement, education, and technological innovations to reduce underage experimentation while preserving the benefits for adult smokers.

With the European elections approaching, it is crucial for policymakers to understand the importance of harm reduction strategies. Our findings support a balanced approach that protects public health and helps smokers transition to safer alternatives.”

The reports can be downloaded at www.tholosfoundation.org/thr.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Tim Andrews, tandrews@tholosfoundation.org

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SLB OneSubsea awarded subsea boosting contract by Petrobras for the Búzios field, offshore Brazil12.12.2024 14:22:00 CET | Press Release

Global energy technology company SLB (NYSE: SLB) today announced a contract award by Petrobras, following a competitive tender, to its OneSubsea™ joint venture for two subsea raw seawater injection (RWI) systems to increase recovery from the prolific Búzios field. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241212795762/en/ Under the contract, SLB OneSubsea will provide two complete subsea RWI systems to support Petrobras’ FPSOs P-74 and P-75, and they will each consist of a subsea seawater injection pump, umbilical system and topside variable speed drive. (Photo: Business Wire) The subsea RWI systems will help to increase the production of floating production storage and offloading (FPSO) vessels, which are currently bottlenecked in their water injection capacities. Once operational, the RWI systems will reduce greenhouse gas (GHG) emissions per barrel of oil as they are a more efficient means of reservoir pressurization

EnerSys Wins Prestigious German ESG Transparency Award12.12.2024 14:15:00 CET | Press Release

EnerSys(NYSE: ENS), the global leader in stored energy solutions for industrial applications, is proud to announce it has been honored with the German ESG Transparency Award. This distinguished accolade recognizes organizations that demonstrate exemplary transparency and accountability in their environmental, social, and governance (ESG) initiatives. The ESG Transparency Award, presented annually in Germany, highlights the importance of clear and comprehensive ESG reporting as a cornerstone of corporate responsibility. This recognition underscores EnerSys’ steadfast commitment to sustainable practices and its leadership in advancing ESG standards within the industrial energy sector. “Receiving the ESG Transparency Award is a tremendous honor and a testament to EnerSys' dedication to transparency and continuous improvement in our global sustainability journey. At EnerSys, we believe in ‘Powering the Future, Everywhere for Everyone,’ and this recognition underscores our commitment to con

Parse Biosciences Launches Evercode Mouse BCR to Support Antibody Engineering and Development for Drug Discovery Applications12.12.2024 14:15:00 CET | Press Release

Parse Biosciences, a leader in scalable single cell sequencing solutions, today announced the expansion of its Evercode BCR™ product line to enable applications in mice. The new kits enable researchers to profile the mouse BCR repertoire alongside whole transcriptome data for millions of cells in a single experiment, offering unmatched scale and efficiency for antibody discovery. The Evercode BCR platform is designed to streamline workflows for antibody research, allowing scientists to identify individual antibody-producing cells and their clonally-related groups that generate specific antibodies of interest. Unique features, such as sample fixation capabilities, allow researchers to preserve cells and samples from mice for up to six months, thereby reducing the need to harvest additional mice and maximizing the yield per discovery campaign. Further, the technology eliminates the requirement for costly equipment, making advanced single cell analysis accessible with standard laboratory

1NCE Trains Software Innovators on Simplifying IoT Solutions12.12.2024 14:15:00 CET | Press Release

1NCE, one of the fastest-growing companies in the Internet of Things (IoT), announces the launch of its Certified Integrators Program (CIP). The program empowers external software developers to integrate seamlessly with 1NCE’s IoT platform, simplifying the development of connected solutions and enhancing customer success. The program marks a new step for 1NCE’s Partner Initiative, which counts more than 80 companies supporting 1NCE and its 23,000 customers managing 30 million endpoints worldwide. By offering hands-on training and certification, 1NCE equips integrators with tools to deliver streamlined, cost-effective IoT implementations for businesses across industries. A key aspect of 1NCE's strategy is its dedication to providing open access, enabling top software developers to collaboratively build connected products on the 1NCE platform. The CIP starts with a comprehensive education program for partners to become certified experts in 1NCE’s IoT platform, then continues with teachin

Tanner Pharma Expands Global Access to Botensilimab and Balstilimab Through Partnership With Agenus12.12.2024 14:00:00 CET | Press Release

Tanner Pharma, a global provider of specialty medicine access solutions, today announced a collaboration with Agenus, a leading immuno-oncology company, to provide expanded access to botensilimab (BOT) and balstilimab (BAL). Through a Named Patient Program (NPP), this initiative offers patients with microsatellite stable colorectal cancer (MSS CRC) and other advanced solid tumors the opportunity to access BOT/BAL based on supporting clinical evidence and medical need. Tanner Pharma will manage access to BOT/BAL for patients in geographies that allow named patient access to investigational medicines. The NPP ensures that patients, in consultation with their physicians, can access BOT/BAL even before regulatory approval, adhering to all ethical and compliance standards. BOT and BAL are investigational immunotherapies designed to target challenging cancers, including MSS CRC and other tumors historically resistant to immune-based treatments. Clinical outcomes have demonstrated complete pa

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye